New Japanese Regenerative Medicine Legislation and Commercial … – Wall Street Journal
|
New Japanese Regenerative Medicine Legislation and Commercial …
Wall Street Journal 25, 2013 (GLOBE NEWSWIRE) — Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a framework for accelerated approval of stem cell products in Japan, the world’s … |
